R&D | May 25, 2026
AbbVie signals major oncology momentum at ASCO
With standout ADC and t-cell engager response data across hard-to-treat cancers
With standout ADC and t-cell engager response data across hard-to-treat cancers
The standout story remains Wegovy, particularly its new oral formulation
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The company’s Growth Portfolio delivered $6.2 billion in revenue
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
The dispute stems from an earlier circular by Zuventus allegedly accusing Zorvia of market sabotage
Funding to accelerate growth of concierge-style private health services and Aayu’s paperless hospital infrastructure platform
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Subscribe To Our Newsletter & Stay Updated
